Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and settlement of equity awards. On August 21, 2026, 264 Restricted Stock Units were converted into 264 shares of Common Stock at $0.00 per share. Following these transactions, he holds 10,010 Common shares and 6,864 RSUs, all as direct ownership. The RSUs were from a November 8, 2024 grant that vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the next three years.
Guardant Health, Inc. (GH) received a Rule 144 notice relating to proposed sales of its common stock for the account of officer AmirAli Talasaz. The notice covers up to 37,500 shares, described as founder shares acquired from the issuer on September 22, 2018, with sales to be effected through Stifel Nicolaus & Company Inc. The filing also lists prior sales of Guardant Health common stock by AmirAli Talasaz over the past three months.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported the vesting and conversion of restricted stock units into common stock. On August 17, 2026, 232 restricted stock units were converted into 232 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he held 4,788 shares of common stock directly and 5,337 restricted stock units, which continue to vest under an award granted on July 17, 2024.
Guardant Health, Inc. (GH) director Tariq Musa reported a combination of RSU vesting and share sales. On August 15, 2026, 250 Restricted Stock Units were converted into 250 shares of common stock, increasing direct holdings to 1,749 shares. On August 17, 2026, he sold 116 common shares at $156.45 per share in an open-market or private transaction. The RSU award was granted on March 6, 2023 and vests over four years, with 25% vested March 15, 2024 and the remaining 75% vesting monthly over the following three years. The filing indicates these transactions were effected under a Rule 10b5-1 trading plan.
Musa Tariq filed a notice to sell 116 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., with an aggregate market value of $18,148.00, on or after August 17, 2026 on NASDAQ. The shares arise from a Restricted Stock Lapse tied to equity compensation that occurred on July 15, 2026. The filing also lists prior sales of Guardant Health common stock over the past three months.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Guardant Health, Inc.. The firm held 6,514,828 shares of Guardant Health common stock, representing 4.9% of the class as of June 30, 2026.
T. Rowe Price reported sole voting power over 6,359,951 shares and sole dispositive power over 6,514,828 shares, with no shared voting or dispositive power. The filer expressly denied that this filing should be construed as an admission of beneficial ownership of these securities.
Guardant Health, Inc. executive Terilyn J. Monroe, Chief People Officer, exercised stock options covering 46,300 shares of common stock on 2026-08-12 (32,288 shares at an exercise price of $20.14 and 14,012 shares at $28.61). She then sold 46,300 common shares in multiple open-market or private transactions at weighted average prices ranging from $162.80 to $168.02. The exercised options were from awards granted on February 26, 2024 and November 8, 2024, each vesting over three years with 33% vesting after roughly one year and the remaining 67% in equal monthly installments over the next two years. The filing does not affirm trading under a Rule 10b5-1 plan.
Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy reported two bona fide gift transactions involving common stock on 2026-08-11. A total of 35,000 shares of Guardant Health common stock were transferred from the Helmy A. Eltoukhy Revocable Trust, reducing that trust’s indirect holdings to 1,995,934 shares. On the same date, 35,000 shares were recorded as acquired as indirect holdings of The Eltoukhy Foundation. A footnote states that these entries reflect changes in form of ownership from the revocable trust to The Eltoukhy Foundation, indicating an internal re-titling of shares rather than an open-market purchase or sale.
Guardant Health, Inc. director and Co-Chief Executive Officer AmirAli Talasaz reported internal transfers of common stock interests involving family entities. On 2026-08-10, 75,000 shares were transferred as a bona fide gift from the Talasaz and Eskandari 2017 Family Trust, reducing that indirect holding to 1,824,351 shares, and 75,000 shares were received by The Talasaz Family Foundation, which now holds 75,000 shares. A footnote states these transactions reflect changes in form of ownership between the trust and the foundation.
Guardant Health, Inc. executive John G. Saia, Chief Legal Officer, reported a bona fide gift of 800 shares of common stock on 2026-08-10. The gift reflects a change in form of ownership due to a transfer to a donor-advised fund within the Saia Family Foundation. Following this charitable transfer, Saia directly holds 38,991 shares of Guardant Health common stock.